在心力衰竭患者的SGLT2抑制期间,节水超过了透性尿液
Adriana Marton1, Seyed Ehsan Saffari2, Manfred Rauh3
1Programme in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, Singapore; Department of Internal Medicine 4-Nephrology and Hypertension, Paracelsus Private Medical School Nuremberg, Nuremberg, Germany.
Journal of the American College of Cardiology
|April 10, 2024
概括
像达帕格利弗洛辛这样的-葡萄糖共运输体2抑制剂 (SGLT-2抑制剂) 在心力衰竭患者中没有增加尿液体积. 生理学节水机制抵消了预期的透性利尿效应,防止了显著的流体损失.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体2 (SGLT-2) 抑制剂越来越多地用于心力衰竭的管理.
- 它们对心脏的益处部分归因于透性利尿效应.
研究的目的:
- 调查血管压素介导的节水是否会取代达帕格利弗洛辛的透性利尿作用.
- 确定达帕格利弗洛辛对心力衰竭患者尿液度和体积的影响.
主要方法:
- 进行了一项单中心,双盲,随机,安慰剂对照试验 (DAPA-Shuttle1).
- 患有慢性心力衰竭的患者 (NYHA I/II类,减少喷射分数) 接受了达帕格利弗洛辛或安慰剂4周.
- 主要终点:尿液溶解酸度的变化;次要终点:可佩水平和自由水清除.
主要成果:
- 达帕格利弗洛辛增加了尿液中的葡萄糖分泌,但没有显著增加尿液体积.
- 血清可佩素水平上升,表明血管压素活性增加.
- 自由水的清除减少,这表明水的再吸收增强.
结论:
- 生理学节水机制有效地抵消了达帕格利弗洛辛的透性尿剂潜力.
- 预期的尿量增加被阻止,突出显示SGLT-2抑制剂治疗心力衰竭患者的适应性反应.
相关概念视频
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Regulation of Water Intake
499
Osmolality refers to the number of solute particles per kilogram of solvent in a solution. Plasma osmolality specifically indicates the total number of solute particles per kilogram of water in blood plasma. This value reflects the body's hydration status and is tightly regulated through mechanisms controlling water intake and output. While water consumption is a conscious decision, the body has intrinsic regulatory systems to maintain fluid balance. Dehydration, a state of water deficit...
499
Antihypertensive Drugs: Potassium-Sparing Diuretics
531
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
531
Antihypertensive Drugs: Action of Diuretics
679
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
679
Antihypertensive Drugs: Thiazide-Class Diuretics
620
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
620
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422


